More than a decade ahead of their patents’ expiration dates, Gilead Sciences is releasing authorized generics of two of its hepatitis C drugs. The launch is planned to happen more than a decade ahead ...

Last September, Gilead made the unexpected move of launching authorized generics to its blockbuster hepatitis C drugs Epclusa and Harvoni, well before their patients expire. Now the copycats have ...

SATURDAY, April 16, 2016 -- Low-cost generic antiviral drugs are as effective and safe as more expensive brand-name drugs in treating people with hepatitis C, researchers report. In many countries, ...

Gilead Sciences isn't letting a few of its own generics interfere with advertising its pan-genotypic hep C drug Epclusa. The Big Biotech is turning to TV again to promote its hep C franchise, this ...

Some Medicare Part D plans did not cover generic versions of pricey hepatitis C drugs in 2019, leaving millions in savings on the table, according to a new watchdog report. The report, released ...

2014-04-04T21:54:23-04:00https://images.c-span.org/Files/203/20140404221121003_hd.jpgWitnesses testified at a hearing on the Food and Drug Administration’s FDA’s ...

There is one fairly new effort for drug companies to mitigate the threat of generic drugs and for biotech companies to mitigate the threat of biosimilars. They can just launch their own. Several large ...